COMP <GO>
GMED vs MRK // EV/EBITDA & P/E VALUATION
Globus Medical Inc. (NYSE) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: GMED 6
— MRK 9
▲ EV/EBITDA & P/E VALUATION LEADER: MRK
LAST: $78.05 (-5.86%) • MKT CAP: $11.13B
valuation
17.6x
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
valuation
15.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GMED VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GMED | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 67.40% | 74.80% | -7.40 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.70% | 20.70% | -12.00 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 17.6x | 15.3x | +2.30 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 5.29% | 3.42% | +1.87 | GMED | /fcf-yield <GO> |
| Operating Margin | 16.30% | 34.30% | -18.00 | MRK | /operating-margins <GO> |
| Net Profit Margin | 18.30% | 28.10% | -9.80 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 16.70% | 1.30% | +15.40 | GMED | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 10.74 | 5.19 | +5.55 | GMED | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | GMED | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 6.60% | +0.50 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.0 | 56.9 | -7.83 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | 0.92 | +0.15 | GMED | /macro-sensitivity <GO> |
| Forward P/E Multiple | 17.4x | 18.4x | -1.00 | GMED | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.13B | $361.02B | -$349.89B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GMED REV | MRK REV | GMED GROSS % | MRK GROSS % | GMED FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.94B | $65.01B | 67.4% | 74.8% | $588.8M | $12.36B |
| FY 2024 | $2.52B | $64.17B | 58.9% | 76.3% | $405.2M | $18.10B |
| FY 2023 | $1.57B | $60.12B | 44.0% | 44.0% | $172.9M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GMED // BETA 1.07
MRK // BETA 0.92